Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02444169 · ClinicalTrials.gov registry record
Retrospective Evaluation of Combination Treatment With the Ulthera System
A clinical trial, sponsored by Ulthera.
- Completed
- Registry status
- 101
- Enrollment target
NCT02444169: Completed study, sponsored by Ulthera.
NCT02444169 is a clinical trial that has completed, run by Ulthera. The registered enrollment target is 101 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02444169 has completed, sponsored by Ulthera.
- COMPLETED
- Registry status
- 101 participants
- Enrollment target
Study Summary
A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.
Primary Outcome
An assessment of adverse events through chart review will evaluate the safety of combination treatments of Ultherapy with toxins/fillers.
Interventions
- DEVICE Radiesse
- DEVICE Ultherapy
- DRUG Incobotulinumtoxin A
- DEVICE Belotero Balance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-07 |
What the finished NCT02444169 record still lists
NCT02444169 is an observational study that tracks outcomes without assigning an intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Radiesse is the first listed.
NCT02444169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02444169 about?
NCT02444169 is a clinical study titled "Retrospective Evaluation of Combination Treatment With the Ulthera System". A retrospective study to evaluate the Ulthera® System for its potential interaction with toxins and fillers. Up to 500 subjects will be enrolled.
What is the current status of trial NCT02444169?
This trial is currently completed. The enrollment target is 101 participants. The study started on 2015-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02444169?
The interventions under investigation include: Radiesse (DEVICE), Ultherapy (DEVICE), Incobotulinumtoxin A (DRUG), Belotero Balance (DEVICE).
Who is sponsoring clinical trial NCT02444169?
This trial is sponsored by Ulthera, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia